- Home>
- Journal Watch
- >
- ribavirin
Search for ribavirin in all Journal Watch editions
Physician-authored summaries on the latest research on ribavirin, editorials on ribavirin, and perspectives on ribavirin - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 216 results - Relevance
- Date
You searched for: ribavirin
-
Sofosbuvir plus Peginterferon and Ribavirin for Chronic HCV Infection Free
- April 12, 2013
- Atif Zaman, MD, MPH
- Gastroenterology
In phase II trials, a 12-week regimen resulted in high virologic response 24 weeks after treatment, no sofosbuvir-specific adverse effects, and no virologic breakthrough.- Reviewing:
- Lawitz E et al., Lancet Infect Dis 2013 Mar 15;: Kowdley KV et al., Lancet 2013 Mar 15;:
-
In HIV/HCV-Coinfected Patients, Should Ribavirin Dosing Be Weight-Based?
- June 4, 2012
- Rajesh T. Gandhi, MD
- HIV/AIDS
A randomized study suggests that weight-based dosing is not better than using a fixed dose, but controversy persists.- Reviewing:
- Rodriguez-Torres M et al., HIV Clin Trials 2012 May/Jun; 13:142.
-
Taribavirin vs. Ribavirin for Chronic Hepatitis C Virus Infection
- December 17, 2010
- Atif Zaman, MD, MPH
- Gastroenterology
Virologic response rates were similar with both regimens; anemia was less common with taribavirin.- Reviewing:
- Poordad F et al., Hepatology 2010 Oct; 52:1208.
-
Peginterferon plus Ribavirin for HBeAg-Negative Chronic Hepatitis B Infection
- October 22, 2010
- Atif Zaman, MD, MPH
- Gastroenterology
Combination therapy did not provide any benefits over peginterferon alone.- Reviewing:
- Rijckborst V et al., Am J Gastroenterol 2010 Aug; 105:1762.
-
Viramidine vs. Ribavirin for Hepatitis C Infection
- November 6, 2009
- Atif Zaman, MD, MPH
- Gastroenterology
The ribavirin prodrug viramidine failed to demonstrate noninferiority to ribavirin in achieving sustained virologic response rates.- Reviewing:
- Benhamou Y et al., Hepatology 2009 Sep; 50:717.
-
Peginterferon and Ribavirin for Dual HCV and HBV Infection
- May 8, 2009
- Atif Zaman, MD, MPH
- Gastroenterology
Sustained virologic response rates were similar for patients dually infected with any genotype of HCV and HBV and for HCV-monoinfected patients.- Reviewing:
- Liu C-J et al., Gastroenterology 2009 Feb; 136:496.
-
Peginterferon and Ribavirin for Difficult-to-Treat HCV: Is More Better?
- December 12, 2008
- Atif Zaman, MD, MPH
- Gastroenterology
Data from a pilot study suggest that higher doses of peginterferon and ribavirin for chronic HCV infection leads to lower relapse rates in difficult-to-treat cases.- Reviewing:
- Fried MW et al., Hepatology 2008 Oct; 48:1033.
-
Is Short-Duration Peginterferon plus Ribavirin Therapy for Hepatitis C Cost-Effective?
- December 7, 2007
- Atif Zaman, MD, MPH
- Gastroenterology
When baseline viral load and RVR are taken into account, short therapy might be cost-effective.- Reviewing:
- Nakamura J et al., Eur J Gastroenterol Hepatol 2007 Sep; 19:733.
-
Peginterferon plus Ribavirin for 16 or 24 Weeks for Genotype 2 or 3 HCV Infections Free
- July 11, 2007
- Atif Zaman, MD, MPH
- Gastroenterology
Not all patients do well with a shorter treatment regimen.- Reviewing:
- Shiffman ML et al., N Engl J Med 2007 Jul 12; 357:124-34. Liang TJ., N Engl J Med 2007 Jul 12; 357:176-8.
-
Reducing Peginterferon and Ribavirin Doses in Patients with Genotype 1 HCV Infections
- April 27, 2007
- Atif Zaman, MD, MPH
- Gastroenterology
Sustained response rates were not affected by dose reductions, as long as patients received at least 60% of optimal doses of PEG-IFN and RBV.- Reviewing:
- Reddy KR et al., Clin Gastroenterol Hepatol 2007 Jan; 5:124-9. Shiffman ML et al., Gastroenterology 2007 Jan; 132:103-12.
-
Retreatment of HCV-Positive Nonresponders with Peginterferon and Ribavirin
- August 25, 2006
- Atif Zaman, MD, MPH
- Gastroenterology
In this prospective study of HCV-positive patients with previous nonresponse to interferon plus ribavirin, retreatment with pegylated interferon plus ribavirin led to an SVR rate of about 20%.- Reviewing:
- Taliani G et al., Gastroenterology 2006 Apr; 130:1098-106.
-
Consensus Interferon plus Ribavirin for Previous Nonresponders to HCV Therapy
- April 11, 2006
- Atif Zaman, MD, MPH
- Gastroenterology
Daily consensus interferon plus ribavirin was associated with an SVR rate of 22% in HCV-positive patients with previous nonresponse to interferon plus ribavirin.- Reviewing:
- Cornberg M et al., J Hepatol 2006 Feb; 44:291-301.
-
Peginterferon Plus Ribavirin for Certain HCV Patients: Shorter Is Better
- July 26, 2005
- Atif Zaman, MD, MPH
- Gastroenterology
A variable-duration regimen for patients with HCV genotype 2 or 3 infections is an effective strategy that reduces costs and improves tolerability.- Reviewing:
- Mangia A et al., N Engl J Med 2005 Jun 23; 352:2609-17.
-
Response to Interferon-α/Ribavirin Does Not Decrease on Retreatment of Hepatitis C
- September 19, 2012
- Neil M. Ampel, MD
- Infectious Diseases
Among study participants with the same end-of-study response status, HCV RNA declines at 4 weeks were similar between treatment-naive patients and treatment-experienced ones.- Reviewing:
- Liu J et al., Clin Infect Dis 2012 Sep 1; 55:639.
-
Cost-Effectiveness of Pegylated Interferon-Alfa and Ribavirin in HCV/HIV-Coinfected Patients
- March 14, 2007
- Neil M. Ampel, MD
- Infectious Diseases
A computer-based model showed increased life expectancy at an acceptable cost; benefits were greatest for patients with non–genotype-1 HCV infections.- Reviewing:
- Campos NG et al., Am J Med 2007 Mar; 120:272-9.
-
Are Erythropoietic Growth Factors Cost-Effective for Treatment of Ribavirin-Induced Anemia in HCV Patients?
- December 13, 2005
- Atif Zaman, MD, MPH
- Gastroenterology
Adjuvant therapy with erythropoietic growth factors might be cost-effective for treatment-induced anemia in HCV patients.- Reviewing:
- Spiegel BM et al., Clin Gastroenterol Hepatol 2005 Oct; 3:1034-42.
-
All-Oral Interferon-Free Treatment for Patients with Hepatitis C
- January 29, 2013
- Allan S. Brett, MD
- General Medicine
Responses were impressive in some subgroups.- Reviewing:
- Gane EJ et al., N Engl J Med 2013 Jan 3; 368:34. Poordad F et al., N Engl J Med 2013 Jan 3; 368:45.
-
Interferon-Free Regimens for Chronic HCV Infection: Getting Closer
- January 2, 2013
- Atif Zaman, MD, MPH
- Gastroenterology
Several regimens with polymerase or protease inhibitors plus ribavirin achieved high sustained virologic response rates without interferon.- Reviewing:
- Gane EJ et al., N Engl J Med 2013 Jan 3; 368:34. Poordad F., N Engl J Med 2013 Jan 3; 368:45.
-
Interferon-Free Regimen Shows Promise for Chronic HCV Infection Free
- September 30, 2011
- Atif Zaman, MD, MPH
- Gastroenterology
In a phase Ib trial, the combination of a polymerase inhibitor, a protease inhibitor, and ribavirin demonstrated potent antiviral activity.- Reviewing:
- Zeuzem S et al., Gastroenterology 2011 Sep 16;:
-
Treatment-Induced Anemia in Patients with Hepatitis C Virus Infection
- February 4, 2011
- Atif Zaman, MD, MPH
- Gastroenterology
Variants of the ITPA gene were associated with reduced ribavirin-induced hemolytic anemia but not sustained virologic response.- Reviewing:
- Thompson AJ et al., Gastroenterology 2010 Oct; 139:1181.
Sort by:
Items 1 to 20 of 216 results - Relevance
- Date
